VRAX
Virax Biolabs Group Limited · NASDAQ
- Market cap
- $602,555
Virax Biolabs Group Limited (VRAX) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for VRAX, including 3 SEC filings, 1 insider trade and 1 leadership change. The most recent was published Nov 18, 2026.
Financial highlights
Full financials- Revenue, FY2026
- $12.4K
- Revenue growth
- +96.2%
- Net income, FY2026
- -$5.02M
- Net margin
- -40439.1%
- Free cash flow, FY2026
- -$4.88M
- Cash
- $6.44M
For fiscal 2026 (ended Mar 31, 2026), from SEC filings. Not investment advice.
News · 26 weeks27+100%
2026-05-242026-11-15
Mix1090d
- SEC Filings7(70%)
- Other1(10%)
- Insider1(10%)
- Leadership1(10%)
Activity · 52 weeks5132 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland ChinaThree new distributor agreements build on initial China sales and extend the Company's distributor-led commercial strategyLONDON, Oct. 29, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. for its ImmuneSelect research-use immune profiling products. ImmuneSelect is Virax's commercially available research-use-only ("RUO") immune pro
- INSIDERSEC Form 3 filed by Virax Biolabs Group Limited3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 424B5 filed by Virax Biolabs Group Limited424B5 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form EFFECT filed by Virax Biolabs Group LimitedEFFECT - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECAmendment: SEC Form F-3/A filed by Virax Biolabs Group LimitedF-3/A - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form F-3 filed by Virax Biolabs Group LimitedF-3 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply AgreementFiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 millionFosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian marketsPreferred investment option exercise, completed July 10, 2026, generated approximately $3.3 million in gross proceeds, further strengthening the Company's liquidity position and balance sheetNasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirementLONDON, July 16, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross ProceedsLONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos. 333-292241 and 333-275893). The gross p
- PRThese Companies Just Dropped Major Growth CatalystsDENVER, July 10, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. Virax Expands into Southeast Asia Through Exclusive Fosun Diagnostics Partnership Virax Biolabs (NASDAQ:VRAX) announced a significant commercial milestone by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia. The agreement allows immediate
- PRVirax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross ProceedsLONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun DiagnosticsLONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.
- SECSEC Form 20-F filed by Virax Biolabs Group Limited20-F - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Group Limited Announces 1-for-25 Share ConsolidationLONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of the Company's authorized, issued and outstanding ordinary shares of US$0.001 par value each at a ratio of 1-for-25 effective 26 June 2026 (the "Share Consolidation"). The shareholders approved the Share Consolidation at the adjourned extraordinary general meeting of the shareholders held on Friday, June 12, 2026, at 2.00 p.m. local time at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire. At the opening of trading on June 26, 2026, the Company's ordinary shares will begin trading on a post-S
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
VRAX FAQ
11 questionsWhat does Virax Biolabs Group Limited do?
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that...What is the latest news on VRAX?
In the last 30 days Quantisnow tracked 5 wire items for VRAX: 3 SEC filings, 1 insider trade and 1 leadership change. The most recent was published on November 18, 2026.What is VRAX revenue?
Virax Biolabs Group Limited (VRAX) reported $12.4K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 96.2% from the year before.Is VRAX profitable?
No. Virax Biolabs Group Limited reported a net loss of $5.02M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does VRAX have?
Virax Biolabs Group Limited reported $6.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does VRAX stock trade?
Virax Biolabs Group Limited (VRAX) is listed on NASDAQ.What sector and industry is VRAX in?
Virax Biolabs Group Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Virax Biolabs Group Limited go public?
Virax Biolabs Group Limited (VRAX) completed its IPO in 2022.What are analysts saying about VRAX?
Virax Biolabs Group Limited has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $3.00 price target on 2025-03-31. Recent price targets cluster around $3.00.What companies are similar to VRAX?
Notable peers in the same industry include ABT (Abbott Laboratories), CODX (Co-Diagnostics Inc.), OSUR (OraSure Technologies Inc.), QDEL (QuidelOrtho Corporation). Compare VRAX side-by-side with any of them on Quantisnow.How can I track VRAX on Quantisnow?
Quantisnow aggregates Virax Biolabs Group Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRAX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change